Rare diseases can be caused by genetic mutations that disrupt normal pre-mRNA splicing. Antisense oligonucleotide treatment to the splicing thus has therapeutic potential for many rare diseases. In this review we will focus on the state of the art on exon skipping using antisense oligonucleotides as a potential therapy for rare genetic diseases, outlining how this versatile approach can be exploited to correct for different mutations.
Keywords: Antisense oligonucleotides; Exon skipping; Rare disease; Splicing.
Copyright © 2014 Elsevier Inc. All rights reserved.